An Open-Label, Single-Ascending Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Elderly (≥65 Years of Age) Japanese, and Healthy Younger Adult Japanese Subjects (20 to 55 Years of Age, Inclusive)

Trial Profile

An Open-Label, Single-Ascending Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Elderly (≥65 Years of Age) Japanese, and Healthy Younger Adult Japanese Subjects (20 to 55 Years of Age, Inclusive)

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Mar 2017

At a glance

  • Drugs Esketamine (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 21 Feb 2017 Status changed from recruiting to completed.
    • 13 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Jan 2017.
    • 13 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jan 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top